+ Follow DR. DONALD EASTON Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 347113
[Title] => Benefits of clopidogrel in patients with cardiovascular disease reaffirmed
[Summary] => Taking the anti-clotting medicine clopidogrel together with aspirin is beneficial to patients with known cardiovascular disease or those who suffered a heart attack or stroke, but not in patients who only have risk factors for developing a cardiovascular disease, according to the results of an international study called CHARISMA.
[DatePublished] => 2006-07-13 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 256781
[Title] => Neurologists hail results of new study
[Summary] => A well-respected neurologist and medical researcher from Hong Kong recently presented the results of the MATCH trial, the largest study conducted to date in a high-risk population of cerebrovascular patients.
In a symposium at the Philippine Neurological Association’s 10th mid-year convention held on Panglao Island in Bohol, Dr. Lawrence Wong discussed the trial results which he considers a breakthrough in the management of cerebrovascular diseases.
His presentation was entitled "Risk Stratification for Secondary Stroke Prevention."
[DatePublished] => 2004-07-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
DR. DONALD EASTON
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 347113
[Title] => Benefits of clopidogrel in patients with cardiovascular disease reaffirmed
[Summary] => Taking the anti-clotting medicine clopidogrel together with aspirin is beneficial to patients with known cardiovascular disease or those who suffered a heart attack or stroke, but not in patients who only have risk factors for developing a cardiovascular disease, according to the results of an international study called CHARISMA.
[DatePublished] => 2006-07-13 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 256781
[Title] => Neurologists hail results of new study
[Summary] => A well-respected neurologist and medical researcher from Hong Kong recently presented the results of the MATCH trial, the largest study conducted to date in a high-risk population of cerebrovascular patients.
In a symposium at the Philippine Neurological Association’s 10th mid-year convention held on Panglao Island in Bohol, Dr. Lawrence Wong discussed the trial results which he considers a breakthrough in the management of cerebrovascular diseases.
His presentation was entitled "Risk Stratification for Secondary Stroke Prevention."
[DatePublished] => 2004-07-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
